Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Healthcare Sector Analysis

UpdatedNov 03, 2025
DataAggregated Company Financials
Companies34
  • 7D-2.1%
  • 3M1.6%
  • 1Y-0.6%
  • YTD4.6%

Over the last 7 days, the Healthcare industry has dropped 3.1%, driven by Novartis declining 3.8%. On the other hand Galderma Group is actually up 6.3%. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to grow by 14% annually.

Sector Valuation and Performance

Has the Swiss Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 03 Nov 2025CHF 603.1bCHF 155.2bCHF 24.9b32.5x24.2x3.9x
Wed, 01 Oct 2025CHF 596.8bCHF 153.5bCHF 24.2b31.6x24.7x3.9x
Fri, 29 Aug 2025CHF 612.9bCHF 154.0bCHF 24.3b33.4x25.2x4x
Sun, 27 Jul 2025CHF 601.5bCHF 152.9bCHF 24.1b31.2x25x3.9x
Tue, 24 Jun 2025CHF 581.1bCHF 151.0bCHF 22.4b30x25.9x3.8x
Thu, 22 May 2025CHF 581.4bCHF 151.9bCHF 22.6b32.1x25.7x3.8x
Sat, 19 Apr 2025CHF 545.7bCHF 149.9bCHF 21.8b25.9x25.1x3.6x
Mon, 17 Mar 2025CHF 618.1bCHF 155.1bCHF 22.5b31.2x27.5x4x
Wed, 12 Feb 2025CHF 630.6bCHF 156.6bCHF 22.5b30x28x4x
Fri, 10 Jan 2025CHF 593.8bCHF 153.2bCHF 24.6b29.9x24.1x3.9x
Sun, 08 Dec 2024CHF 571.1bCHF 150.7bCHF 24.2b28.9x23.6x3.8x
Tue, 05 Nov 2024CHF 601.4bCHF 149.4bCHF 24.0b29.8x25.1x4x
Thu, 03 Oct 2024CHF 602.5bCHF 147.1bCHF 22.3b32.4x27x4.1x
Sat, 31 Aug 2024CHF 631.7bCHF 147.3bCHF 22.3b32.7x28.3x4.3x
Mon, 29 Jul 2024CHF 615.0bCHF 149.1bCHF 22.5b32.1x27.3x4.1x
Wed, 26 Jun 2024CHF 578.5bCHF 148.7bCHF 22.7b35.2x25.5x3.9x
Fri, 24 May 2024CHF 562.1bCHF 150.2bCHF 22.9b34.1x24.5x3.7x
Sun, 21 Apr 2024CHF 539.2bCHF 145.0bCHF 22.3b35.3x24.2x3.7x
Tue, 19 Mar 2024CHF 533.0bCHF 143.6bCHF 22.2b37.5x24x3.7x
Thu, 15 Feb 2024CHF 517.4bCHF 143.1bCHF 22.4b32.6x23.1x3.6x
Sat, 13 Jan 2024CHF 544.6bCHF 151.4bCHF 21.8b27.5x25x3.6x
Mon, 11 Dec 2023CHF 521.5bCHF 153.4bCHF 22.0b25.5x23.7x3.4x
Wed, 08 Nov 2023CHF 502.5bCHF 154.8bCHF 22.2b23.6x22.7x3.2x
Fri, 06 Oct 2023CHF 524.4bCHF 146.1bCHF 21.3b31.4x24.7x3.6x
Sun, 03 Sep 2023CHF 545.5bCHF 144.3bCHF 21.1b29.8x25.8x3.8x
Tue, 01 Aug 2023CHF 561.4bCHF 146.3bCHF 22.5b36.5x25x3.8x
Thu, 29 Jun 2023CHF 555.3bCHF 147.2bCHF 22.2b34.7x25x3.8x
Sat, 27 May 2023CHF 579.0bCHF 147.8bCHF 22.3b35x26x3.9x
Mon, 24 Apr 2023CHF 588.1bCHF 146.4bCHF 22.3b33.9x26.3x4x
Wed, 22 Mar 2023CHF 534.4bCHF 148.2bCHF 22.5b31.1x23.7x3.6x
Fri, 17 Feb 2023CHF 543.6bCHF 148.0bCHF 22.7b32.7x23.9x3.7x
Sun, 15 Jan 2023CHF 567.5bCHF 148.6bCHF 38.1b30.7x14.9x3.8x
Tue, 13 Dec 2022CHF 573.8bCHF 149.2bCHF 38.3b31.3x15x3.8x
Thu, 10 Nov 2022CHF 591.9bCHF 150.8bCHF 38.9b29x15.2x3.9x
Price to Earnings Ratio

15.2x


Total Market Cap: CHF 591.9bTotal Earnings: CHF 38.9bTotal Revenue: CHF 150.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Healthcare Sector Price to Earnings3Y Average 24.3x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 24.3x.
  • The industry is trading close to its 3-year average PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 14% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare sector?

CH Market-1.67%
Healthcare-2.05%
Biotech1.75%
Medical Equipment1.31%
Healthtech-2.19%
Pharma-2.34%
Healthcare Services-3.49%
Life Sciences-3.66%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 45.3x.
    • Analysts expect its future annual earnings growth (20.4%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 40% over the next 5 years.
  • This is better than its past earnings decline of 80% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 5.3% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GALD Galderma GroupCHF 148.506.3%
+CHF 2.1b		81.4%PE115.9x
STMN Straumann HoldingCHF 101.0012.9%
+CHF 1.8b		-14.2%PE37.6x
SDZ Sandoz GroupCHF 53.506.7%
+CHF 1.4b		32.6%PE126.2x
MED Medartis HoldingCHF 81.503.4%
+CHF 33.5m		46.8%PS4.3x
PPGN PolyPeptide GroupCHF 26.004.0%
+CHF 33.0m		-21.0%PS2.5x

Latest News

NOVN
CHF 99.27
Novartis
7D
-3.8%
1Y
3.9%

NOVN: Future Trial Data And Pipeline Advancements Will Support Steady Returns

Analysts have raised their fair value estimate for Novartis from $98.60 to $102.12. They cite improved revenue growth outlook and stronger profit margins as key drivers of the upward revision.
SOON
CHF 218.60
Sonova Holding
7D
-4.3%
1Y
-31.5%

SOON: Market Resilience Will Be Tested By Rising Competition And End Market Weakness

Analysts have lowered their average price target for Sonova Holding from CHF 246.65 to CHF 242.47. This reflects a more cautious outlook amid concerns over softer end markets and increased competition.
GALD
CHF 148.50
Galderma Group
7D
6.3%
1Y
81.4%

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.
GALE
CHF 86.60
Galenica
7D
-4.5%
1Y
14.9%

GALE: Stable Outlook As Digital And In-Store Investments Will Support 2025 Guidance

Galenica's analyst price target remains unchanged at CHF 85.50. Analysts cite minimal revisions to growth and margin assumptions since the previous update.
ROG
CHF 258.90
Roche Holding
7D
-3.2%
1Y
-4.9%
IDIA
CHF 3.51
Idorsia
7D
2.3%
1Y
269.3%
ALC
CHF 59.80
Alcon
7D
-1.2%
1Y
-24.6%

Cutting Edge Eye Care Solutions Will Transform Outcomes For Global Aging Populations

Alcon's analyst price target has been revised slightly downward, decreasing by $1.25 to $79.17. Analysts have adjusted their expectations to reflect slightly lower revenue growth and profit margin forecasts.
SFZN
CHF 77.40
Siegfried Holding
7D
-4.1%
1Y
-32.1%

Does Siegfried Holding (VTX:SFZN) Deserve A Spot On Your Watchlist?

Oct 26
Does Siegfried Holding (VTX:SFZN) Deserve A Spot On Your Watchlist?
SDZ
CHF 53.50
Sandoz Group
7D
6.7%
1Y
32.6%

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.
LONN
CHF 554.20
Lonza Group
7D
-4.2%
1Y
2.2%
STMN
CHF 101.00
Straumann Holding
7D
12.9%
1Y
-14.2%

Asia-Pacific And Latin America Will Transform Digital Dentistry

Straumann Holding's analyst price target has been reduced from CHF 116.45 to CHF 111.58, as analysts lower growth expectations in response to a slower than anticipated U.S. recovery and revised margin outlooks. Analyst Commentary Recent analyst revisions reflect a mix of optimism about Straumann Holding's strategic positioning and caution regarding its near-term growth outlook.
KURN
CHF 30.00
Kuros Biosciences
7D
2.8%
1Y
9.9%

Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts

Oct 18
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
PPGN
CHF 26.00
PolyPeptide Group
7D
4.0%
1Y
-21.0%
DESN
CHF 317.00
Dottikon ES Holding
7D
-4.2%
1Y
32.1%

If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity
NWRN
CHF 14.44
Newron Pharmaceuticals
7D
4.5%
1Y
80.5%
MED
CHF 81.50
Medartis Holding
7D
3.4%
1Y
46.8%

Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet

Sep 25
Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet